Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can prostate cancer patients skip hormone therapy? new trial tests SBRT alone

NCT ID NCT06397703

Recruiting now Disease control Sponsor: NYU Langone Health Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is for men with unfavorable intermediate-risk prostate cancer. Participants choose between standard care (6 months of hormone therapy plus high-dose radiation) or radiation alone. The goal is to see if skipping hormone therapy still keeps cancer from returning. About 392 men will be followed for up to 5 years with regular biopsies and PSA tests.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Stereotactic body radiation therapy (SBRT) and androgen deprivation therapy (ADT) using leuprolide, degarelix, or relugolix
What this could lead to
If successful, this could show that SBRT alone is as effective as SBRT plus hormone therapy for controlling intermediate-risk prostate cancer, potentially sparing many men from hormone side effects.
What could go wrong
This is a phase 2 trial with 392 participants, so results are not definitive. The study relies on patient choice rather than random assignment, which may bias outcomes. Long-term follow-up is needed to confirm cancer control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

  • NYU Langone Health

    RECRUITING

    New York, New York, 10016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.